Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy

To develop innovative drug delivery methods the knowledge of a drug's physicochemical properties, namely its ionization constants is essential. Ranolazine and Atenolol are two key drugs used in clinical practice to treat cardiac arrest and their pKa values are important in developing new formulations these drugs. In the present study pKa values were measured experimentally using UV-spectrophotometry, which is known for providing accurate and reproducible pKa values. In pharmaceutical research, the ionization constant (pKa) is an important physicochemical parameter since it determines the dissolving capacity of active substances and to decide the route of administration. The study found that the pKa values for Ranolazine and Atenolol were approximately 7.6 and 9.3, respectively.

UV-spectrophotometry, Ranolazine, Atenolol, pKa value etc

1. Babić S, Horvat AJ, Pavlović DM, Kaštelan-Macan M. Determination of pKa values of active pharmaceutical ingredients. TrAC Trends in Analytical Chemistry. 2007 Dec1;26(11):1043-61. [Google Scholar] [Crossref]

2. Allen RI, Box KJ, Comer JE, Peake C, Tam KY. Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs. Journal of pharmaceutical and biomedical analysis. 1998 Aug 1;17(4-5):699-712. [Google Scholar] [Crossref]

3. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of Ranolazine with Atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Jama. 2004 Jan 21; 291(3): 309-16. [Google Scholar] [Crossref]

4. Sendón, J.L., Lee, S., Cheng, M.L., Ben-Yehuda, O. and CARISA study investigators), 2012. Effects of Ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. European journal of preventive cardiology; 19(5): 952-959. [Google Scholar] [Crossref]

5. Völgyi G, Ruiz R, Box K, Comer J, Bosch E, Takács-Novák K. Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system. Analytica chimica acta. 2007 Feb 5;583(2):418-28. [Google Scholar] [Crossref]

6. Pandey MM, Jaipal A, Kumar A, Malik R, Charde SY. Determination of pKa of felodipine using UV–Visible spectroscopy. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2013 Nov 1;115:887-90. [Google Scholar] [Crossref]

7. Silva FV, Resende S, Araújo AN, Prior JA. Determination of pKa (s) of nilutamide through UV-visible spectroscopy. Microchemical Journal. 2018 May 1;138:303-8. [Google Scholar] [Crossref]

8. Peters CH, Sokolov S, Rajamani S, Ruben PC. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons. Br J Pharmacol. 2013 Jun;169(3):704-16. doi: 10.1111/bph.12150. PMID: 23472826; PMCID: PMC3682716. [Google Scholar] [Crossref]

9. Carl A. Gruetter, Atenolol, xPharm: The Comprehensive Pharmacology Reference,Elsevier;2007:Pages 1-6:ISBN 9780080552323, https://doi.org/10.1016/B978-008055232-3.61259-0. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine